Chapter title |
Measurement of Circulating Progranulin (PGRN/GP88/GEP) by Enzyme-Linked Immunosorbent Assay and Application in Human Diseases
|
---|---|
Chapter number | 7 |
Book title |
Progranulin
|
Published in |
Methods in molecular biology, January 2018
|
DOI | 10.1007/978-1-4939-8559-3_7 |
Pubmed ID | |
Book ISBNs |
978-1-4939-8557-9, 978-1-4939-8559-3
|
Authors |
Ginette Serrero, David Hicks, Serrero, Ginette, Hicks, David |
Abstract |
The enzyme-linked immunosorbent assay (ELISA) is a well-established methodology for detection of analytes in various biological fluids. The assay described herein has been validated for the detection of PGRN/GP88/GEP in blood (serum/ plasma), urine and cerebrospinal fluid (CSF), and synovial fluid and may also be used for breast milk, ductal lavage, nipple aspirates, and saliva. The ability to measure circulating levels of PGRN/GP88/GEP has proven to have clinical utility for several human diseases such as cancer where changes of PGRN/GP88/GEP can be determined as a mean to monitor disease status or response to therapy. In the case of frontotemporal dementia (FTD), the ability to measure PGRN/GP88/GEP levels in plasma and cerebrospinal fluid may be useful in distinguishing PGRN mutation carriers among FTD populations at large. The assay used is a sandwich ELISA where a highly specific antihuman PGRN/GP88/GEP monoclonal antibody is employed as a capture antibody coated on 96-well microplates. After contact with serum (or other bodily fluid), unbound material is washed away before application of another PGRN/GP88/GEP detecting antibody which in turn is detected by a horseradish peroxidase (HRP) conjugated antibody. After further washing to remove all unbound HRP, a substrate (TMB) is added, and after approximately 6 min, a color is developed and can be read as optical density at 620 nm (or 450 nm if using HCL as a stop solution) in a microplate reader. The test described herein is capable of measuring very low levels of PGRN/GP88/GEP such as 0.2 ng/mL as found in CSF of certain FTD patients. Additionally, we have demonstrated the potential clinical utility of measuring the changes of PGRN/GP88/GEP blood levels in cancer patients undergoing therapy. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 16 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 4 | 25% |
Professor | 2 | 13% |
Student > Ph. D. Student | 1 | 6% |
Student > Master | 1 | 6% |
Professor > Associate Professor | 1 | 6% |
Other | 0 | 0% |
Unknown | 7 | 44% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 19% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
Biochemistry, Genetics and Molecular Biology | 2 | 13% |
Arts and Humanities | 1 | 6% |
Unknown | 8 | 50% |